Boc-4-氨基-3-甲基苯甲酸 | 180976-94-7

• 物质功能分类: 生物化工 - 生化试剂 - 氨基酸
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: Boc-4-氨基-3-甲基苯甲酸
• 英文名称: N-Boc-4-amino-3-methylbenzoic acid
• 英文别名: 4-(tert-butoxycarbonylamino)-3-methylbenzoic acid；4-((tert-Butoxycarbonyl)amino)-3-methylbenzoic acid；3-methyl-4-[(2-methylpropan-2-yl)oxycarbonylamino]benzoic acid
• CAS: 180976-94-7
• 化学式: C₁₃H₁₇NO₄
• mdl: MFCD02682225
• 分子量: 251.282
• InChiKey: DATSAXPXARPPIG-UHFFFAOYSA-N

物化性质

• 沸点：
  343.9±35.0 °C(Predicted)
• 密度：
  1.212±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.384
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

反应信息

• 作为反应物：
  描述：

  Boc-4-氨基-3-甲基苯甲酸 在 盐酸 、 lithium hydroxide 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 为溶剂， 反应 13.5h， 生成
  参考文献：
  名称：

  Probing the hydrophobic pocket of farnesyltransferase: aromatic substitution of CAAX peptidomimetics leads to highly potent inhibitors

  摘要：

  Cysteine farnesylation at the carboxylate terminal tetrapeptide CAAX of Ras protein is catalyzed by farnesyltransferase. This lipid modification is necessary for regulatory function of both normal and oncogenic Ras. The high frequency of Ras mutation in human cancers has prompted an intensive study on finding ways of controlling oncogenic Ras function. Inhibition of farnesyltransferase is among the most sought after targets for cancer chemotherapy. We report here the design, synthesis and biological characterization of a series of peptidomimetics as farnesyltransferase inhibitors. These compounds are extremely potent towards farnesyltransferase with IC50 values ranging from subnanomolar to low nanomolar concentrations. They have a high selectivity for farnesyltransferase over the closely related geranylgeranyltransferase-I. Structure-activity relationship studies demonstrated that a properly positioned hydrophobic group significantly enhanced inhibition potency, reflecting an improved complementarity to the large hydrophobic pocket in the CAAX binding site. (C) 1999 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(99)00252-7
• 作为产物：
  描述：

  4-氨基-3-甲基苯甲酸 以4.99 g (60%)的产率得到Boc-4-氨基-3-甲基苯甲酸
  参考文献：
  名称：

  Inhibitors of farnesyltransferase

  摘要：

  公式为C.beta.X的肽类模拟物，其中C代表半胱氨酸，X代表任何自然存在的氨基酸，.beta.代表疏水间隔物，尤其是2-苯基-4-氨基苯甲酸。这些化合物是p2lras法尼基转移酶的有效抑制剂，可以阻断Ras依赖的致癌信号传导，并在动物模型中有效抑制人类肿瘤生长。还披露了通过功能化肽和肽类模拟物的末端氨基和羧基团制备的前药。这些功能化衍生物表现出增加的细胞摄取。还披露了其他结构修饰。

  公开号：

  US05834434A1

文献信息

• Inhibitors of prenyl transferases
  申请人：Univeristy of Pittsburgh

  公开号：US05965539A1

  公开（公告）日：1999-10-12

  Compounds which inhibit prenyl transferases, particularly farnysyltransferase and geranylgeranyl transferase I, processes for preparing the compounds, pharmaceutical compositions containing the compounds, and methods of use.

  抑制戊二烯基转移酶，特别是戊二烯基转移酶和戊二烯基转移酶I的化合物，制备这些化合物的方法，含有这些化合物的药物组合物，以及使用方法。
• LINKER-DRUG AND ANTIBODY-DRUG CONJUGATE (ADC) EMPLOYING THE SAME
  申请人：Industrial Technology Research Institute

  公开号：US20180169262A1

  公开（公告）日：2018-06-21

  A linker-drug represented by formula (I) or a pharmaceutically acceptable salt or solvate thereof is provided. In formula (I), C is a conjugator, L is a linker unit, D is a toxin unit, and n is an integer ranging from 1 to 4. The structure of the conjugator is represented by formula (II). In formula (II), X is a leaving group, each of R 1 and R 2 is independently a single bond or —NH—, and Z is substituted aryl, heteroaryl, linear alkyl, cycloalkyl, heterocycloalkyl, or a combination thereof. The antibody is conjugated to the linker unit through a cysteine residue of the antibody. An antibody-drug conjugate (ADC) employing the above linker-drug is also provided.

  提供由式（I）表示的连接药物或其药学上可接受的盐或溶剂。在式（I）中，C是一个结合物，L是一个连接单元，D是一个毒素单元，n是一个从1到4的整数。结合物的结构由式（II）表示。在式（II）中，X是一个离去基团，R1和R2中的每一个独立地是一个单键或—NH—，Z是取代芳基、杂环芳基、直链烷基、环烷基、杂环烷基或它们的组合。抗体通过抗体的半胱氨酸残基与连接单元结合。还提供了使用上述连接药物的抗体-药物结合物（ADC）。
• A Rhodium-Catalyzed Cascade Cyclization: Direct Synthesis of<i>N</i>-Substituted Phthalimides from Isocyanates and Benzoic Acids
  作者：Xian-Ying Shi、Andrea Renzetti、Soumen Kundu、Chao-Jun Li

  DOI：10.1002/adsc.201300834

  日期：2014.3.10

  A rhodium(III)‐catalyzed amidation between benzoic acids and isocyanates via direct functionalization of an ortho CH bond followed by intramolecular cyclization is described. This cascade cyclization affords N‐substituted phthalimides in one step in 26–91% yields. The reaction is highly atom‐economical, since no theoretical waste except for water is generated in the reaction.

  苯甲酸和异氰酸酯之间的铑（III）催化的酰胺化通过一个的直接官能邻Ç  H键，随后分子内环化进行说明。这种级联环化一步即可提供N取代的邻苯二甲酰亚胺，产率为26-91％。该反应是高度原子经济的，因为在反应中除水外没有产生理论上的浪费。
• Inhibitors of protein isoprenyl transferases
  申请人：University of Pittsburgh

  公开号：US20020193596A1

  公开（公告）日：2002-12-19

  Compounds having the formula 1 or a pharmaceutically acceptable salt thereof wherein R 1 is (a) hydrogen, (b) loweralkyl, (c) alkenyl, (d) alkoxy, (e) thioalkoxy, (f) halo, (g) haloalkyl, (h) aryl-L 2 —, and (i) heterocyclic-L 2 —; R 2 is selected from (a) 2 (b) —C(O)NH—CH(R 14 )—C(O)OR 15 , (c) 3 (d) —C(O)NH—CH(R 14 )—C(O)NHSO 2 R 16 (e) —C(O)NH—CH(R 14 )-tetrazolyl, (f) —C(O)NH-heterocyclic, and (g) —C(O)NH—CH(R 14 )—C(O)NR 17 R 18 ; R 3 is heterocyclic, aryl, substituted or unsubstituted cycloalkyl; R 4 is hydrogen, lower alkyl, haloalkyl, halogen, aryl, arylakyl, heterocyclic, or (heterocyclic)alkyl; L 1 is absent or is selected from (a) —L 4 —N(R 5 )—L 5 —, (b) —L 4 —O—L 5 —, (c) —L 4 —S(O) n —L 5 — (d) —L 4 -L 6 —C(W)—N(R 5 )—L 5 —, (e) —L 4 -L 6 —S(O) m —N(R 5 )—L 5 —, (f) —L 4 —N(R 5 )—C(W)—L 7 -L 5 —, (g) —L 4 —N(R 5 )—S(O) p —L 7 —L 5 —, (h) optionally substituted alkylene, (i) optionally substituted alkenylene, and (j) optionally substituted alkynylene are inhibitors of protein isoprenyl transferases. Also disclosed are protein isoprenyl transferase inhibiting compositions and a method of inhibiting protein isoprenyl transferases.

  具有以下公式的化合物或其药学上可接受的盐，其中R1为(a)氢，(b)较低的烷基，(c)烯基，(d)烷氧基，(e)硫代烷氧基，(f)卤素，(g)卤代烷基，(h)芳基-L2—，以及(i)杂环-L2—；R2从(a)中选择，(b) -C(O)NH-CH(R14)-C(O)OR15，(c)中选择，(d) -C(O)NH-CH(R14)-C(O)NHSO2R16，(e) -C(O)NH-CH(R14)-四唑基，(f) -C(O)NH-杂环，以及(g) -C(O)NH-CH(R14)-C(O)NR17R18；R3为杂环，芳基，取代或未取代的环烷基；R4为氢，较低烷基，卤代烷基，卤素，芳基，芳基烷基，杂环基，或(杂环)烷基；L1为空缺或从(a) -L4-N(R5)-L5-，(b) -L4-O-L5-，(c) -L4-S(O)n-L5-，(d) -L4-L6-C(W)-N(R5)-L5-，(e) -L4-L6-S(O)m-N(R5)-L5-，(f) -L4-N(R5)-C(W)-L7-L5-，(g) -L4-N(R5)-S(O)p-L7-L5-，(h)可选择取代的烷基，(i)可选择取代的烯基，以及(j)可选择取代的炔基是蛋白异戊二烯转移酶的抑制剂。还公开了蛋白异戊二烯转移酶抑制组合物和抑制蛋白异戊二烯转移酶的方法。
• [EN] 2-ARYLSULFONAMIDO-N-ARYLACETAMIDE DERIVATIZED STAT3 INHIBITORS<br/>[FR] INHIBITEURS DE STAT3 DÉRIVÉS DE 2-ARYLSULFONAMIDO-N-ARYLACÉTAMIDE
  申请人：UNIV HAWAII

  公开号：WO2018136935A1

  公开（公告）日：2018-07-26

  The present disclosure provides pharmaceutical compositions comprising 2-arylsulfonamido-N-arylacetamide derivatized Stat3 inhibitors and certain pharmaceutically acceptable salts thereof, and methods of their use.

  本公开提供了含有2-芳基磺酰胺基-N-芳基乙酰胺衍生的Stat3抑制剂及其某些药用盐的制药组合物，以及它们的使用方法。